Note 13 - Business Segment Reporting

12 Months Ended

Dec. 31, 2018

Segment Reporting Disclosure [Text Block]

13.

Business Segment Reporting

The Company manages its operations as

one

segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are though

one

independent distributor, which is the only customer greater than

10%

of sales. The Company’s revenues by geographic region are as follows (in thousands):

	Year Ended December 31,
	2018		2017		2016
Consolidated Revenue:
United States	$	29,189	$	26,327	$	25,608
Brazil		13,046		13,069		13,083
Other		439		305		289
Total Revenue	$	42,674	$	39,701	$	38,980

All the Company’s operations are in the United States. Assets in Brazil consist primarily of Cash, Cash Equivalents and Marketable Securities. The Company’s assets by geographic region are as follows (in thousands):

	As of December 31,
Assets:	2018		2017
United States	$	20,314	$	18,434
Brazil		4,660		8,074
Total Assets	$	24,974	$	26,508